

## IMMUNOTHERAPIES

<b>TILs:</b> aAPCs that expresses an anti-CD3 scFv transmembrane to determine the cytotoxicity of TILs	21MB083
<b>CLEC12A:</b> Novel CLEC12A scFv Targeting CAR-T cells for Acute Myeloid Leukemia Immunotherapy	21MB064N
<b>CD40:</b> CD40 Agonist improves ex-vivo TIL expansion for immunotherapy	21MA018
<b>T cell:</b> T cells expressing anti-CD3 antibodies autoactivate and decrease expression of T cell receptors to treat GVHD, or make T cells suitable for off-the-shelf treatment of allogeneic subjects	21MA013N
<b>ITAM:</b> Human ITAM Mutated Variants For Better Intracellular Signaling Domains For Gamma-Delta CAR T-Cell Activation	21MA008N
<b>ESR1:</b> Cancer Vaccine Using Novel ESR1 Derived Peptides For Neoantigen Therapy	20MB062N
<b>NOTCH:</b> Single-domain antibodies (nanobodies) targeting the notch ligand DLL4 to Disrupt the interaction of DLL4 and Notch1 for GVHD	20MB053N
<b>CD33 CD123 NKG2DL:</b> Bispecific Gamma Delta CAR-T Cells that Recognize CD33, CD123 and NKG2D Ligands for the Treatment of Acute Myeloid Leukemia	20MB050N
<b>OR2H1 or OR5V1:</b> Olfactory Receptor Targeting Chimeric Antigen Receptor Expressing T cell (CAR-T) for Solid Tumors	20MA027
<b>CD33 CD123:</b> Novel Bispecific CD33 CD123 scFv CAR-T Cells for Acute Myeloid Leukemia Immunotherapy	20MA024
<b>HER-2:</b> Combination Therapy of a HER2-DC1 Dendritic Cell Cancer Vaccine and a Probiotic	20MA016N
<b>TILs:</b> 12 Chemokine Gene Expression Signature to Increase the Efficacy of Manufacturing Tumor Infiltrating Lymphocytes	20MA013N
<b>PERK, IRE1:</b> Method of Enhancing Immunotherapy Using ER Stress Pathway Inhibitors	20MA005
<b>PGC-1<math>\alpha</math>:</b> CAR T Cells Engineered to Express PGC-1 alpha Demonstrate Enhanced Metabolic Fitness	19MB066
<b>PGC-1<math>\alpha</math>:</b> N-Terminal Mutant PGC-1 $\alpha$ Overexpression Enhances Metabolic Fitness Reducing CAR-T Exhaustion while Maintaining Proliferative Capacity	19MB066T2
<b>TILs:</b> Fucose increases tumor cell HLA-DRB1 expression increasing CD4+ T-cell activation with synergistic tumor killing activity with anti-PD1 checkpoint inhibitors	19MB049N

Haskell Adler PhD MBA CLP  
Sr. Licensing Manager  
[haskell.adler@moffitt.org](mailto:haskell.adler@moffitt.org)  
(813) 745-6596

Charlie Shaw PhD  
Associate Director, Licensing  
[charlie.shaw@moffitt.org](mailto:charlie.shaw@moffitt.org)  
(813) 745-6639

Praba Soundararajan PhD  
Intellectual Property Manager  
[praba.soundararajan@moffitt.org](mailto:praba.soundararajan@moffitt.org)  
(813) 745-6776

## IMMUNOTHERAPIES

<b>Antibodies:</b> Fully Human Anti-BDNF Antibodies	19MB048N
<b>Antibodies:</b> Fully Human Anti-TSPAN7 Antibodies	19MB047N
<b>T-Bet:</b> T-Bet Transcription Factor Armed CAR-T Cells Maintain Memory Phenotypes and Rescue CD4 Cells Leading to Increased Persistence	19MA035N
<b>EGFR, MUC1:</b> Bispecific CAR-T Cell Constructs (Chimeric Antigen Receptors) that Recognize EGFR and MUC1 for the Treatment of Lung Cancer	19MA033N
<b>Bispecific T-Cell Engagers:</b> B-Cells Engineered to Express Bispecific T-Cell Engagers Result in Longer Engager Half Lives	19MA029N
<b>NOTCH:</b> Modified Delta-like 4 (DLL4) Ligands with Increased Affinity for Multiple Notch Receptors Enhance the Efficacy of Adoptive T-cell Immunotherapy	19MA026N
<b>aAPC:</b> Artificial Antigen-Presenting Cells Expressing NKG2D Ligands for Producing Anti-NKG2D CAR-T Cells	19MA022N
<b>NKG2D-Ligand:</b> Enhancing Carcinoma Infiltration by NKG2D-Ligand Targeted CAR-T Cells by Co-Expression of the Chemokine Receptor CX3CR1	19MA015NT2
<b>GPC3:</b> Enhancing Carcinoma Infiltration by Anti-GPC3 Targeted CAR-T Cells by Co-Expression of the Chemokine Receptor CX3CR1	19MA015N
<b>B-RAF:</b> Method of Combination Therapy Using B-Raf Inhibitors in Combination with TILs for B-Raf Inhibitor Resistant Melanomas	19MA007
<b>TILs:</b> Enhancing the Anti-Tumor Immunity of TILs by Inhibiting Sirt2	18MB078
<b>CD277:</b> Method of using anti-CD277 antibodies to treat cancer	18MB072N
<b>Antibodies:</b> Fully Human Anti-LAG3 Antibodies	18MB062N
<b>Antibodies:</b> Fully Human Anti-LAG3 Antibodies	18MB061
<b>Brain Mets:</b> CAR-T Cell Constructs with Phage Display Derived Peptide Oligomers that Recognize Lung Cancer Brain Metastases	18MB059
<b>Glioma:</b> Glioma Stem Cell Targeting CAR-T Cell Constructs with Phage Display Derived Peptide Oligomers	18MB054

Haskell Adler PhD MBA CLP  
 Sr. Licensing Manager  
[haskell.adler@moffitt.org](mailto:haskell.adler@moffitt.org)  
 (813) 745-6596

Charlie Shaw PhD  
 Associate Director, Licensing  
[charlie.shaw@moffitt.org](mailto:charlie.shaw@moffitt.org)  
 (813) 745-6639

Praba Soundararajan PhD  
 Intellectual Property Manager  
[praba.soundararajan@moffitt.org](mailto:praba.soundararajan@moffitt.org)  
 (813) 745-6776

## IMMUNOTHERAPIES

<b>Suicide Switch:</b> CAR-T Cells Designed to Self-Destruct if Patient Shows Signs of Toxicity Including GVHD, Cytokine Release Syndrome (CRS), and Neurotoxicity	18MB049N
<b>TLR9 Ligand Trap:</b> TLR9-IgG4 Fusion Protein to Neutralize Innate Immune Activation and Chronic Inflammation Contributing to MDS Pathogenesis	18MB048N
<b>Inflammasome:</b> Small-Molecule Pyrin-Domain Targeted NLRP3 Inflammasome Inhibitors to Neutralize Pyroptotic Cell Death Contributing to MDS Pathogenesis	18MB044N
<b>PSCA:</b> Gamma Delta CAR-T Cell Constructs (Chimeric Antigen Receptors) that Recognize PSCA for CAR by Killing Bone Metastatic Prostate Cancer Cells	18MA037
<b>TILs:</b> Method of Using a Demethylating Agent to Enhance STING Expression and TIL Anti-Tumor Activity in Melanoma	18MA034N
<b>TILs:</b> TILs Modified with CAR Constructs Result in CAR-TILs for Cancer Therapy	18MA033
<b>NKG2D ligands:</b> NKG2D Chimeric Antigen Receptor CAR-T Cells for Acute Myeloid Leukemia Immunotherapy	18MA023
<b>aAPC:</b> Artificial Antigen-Presenting Cells with Heparin-Binding Domain and Protein L for Producing CAR-T Cells	18MA019N
<b>TILs:</b> CD40 Agonist Improves ex-vivo TIL Expansion for Immunotherapy	18MA018
<b>TILs:</b> Method to Increase TILs by Administering Fucose to a Patient	17MB048
<b>CD99:</b> Novel CD99 scFv Targeting CAR-T cells for Acute Myeloid Leukemia Immunotherapy	17MA042
<b>CD99 CLEC12A:</b> Novel Bispecific CD99 CLEC12A scFv CAR-T Cells for Acute Myeloid Leukemia Immunotherapy	17MA042T2N
<b>CLEC12A:</b> Novel CLEC12A scFv Targeting CAR-T cells for Acute Myeloid Leukemia Immunotherapy	17MA041
<b>Inflammasome:</b> Stapled Peptides NLRP3 Inflammasome Inhibitors to Neutralize Pyroptotic Cell Death Contributing to MDS Pathogenesis	17MB037
<b>CD123:</b> Novel CD123 scFv Targeting CAR-T cells for Acute Myeloid Leukemia Immunotherapy	17MA031
<b>CD33, CD123:</b> Bispecific CAR-T Cell Constructs that Recognize CD33 and CD123 for the Treatment of Acute Myeloid Leukemia	17MA030T2

Haskell Adler PhD MBA CLP  
Sr. Licensing Manager  
[haskell.adler@moffitt.org](mailto:haskell.adler@moffitt.org)  
(813) 745-6596

Charlie Shaw PhD  
Associate Director, Licensing  
[charlie.shaw@moffitt.org](mailto:charlie.shaw@moffitt.org)  
(813) 745-6639

Praba Soundararajan PhD  
Intellectual Property Manager  
[praba.soundararajan@moffitt.org](mailto:praba.soundararajan@moffitt.org)  
(813) 745-6776

## IMMUNOTHERAPIES

<b>CD33:</b> Novel CD33 scFv Targeting CAR-T cells for Acute Myeloid Leukemia Immunotherapy	17MA030
<b>TILs:</b> Simple and Rapid Method for Culture of TILs from Melanoma Tumor Fragments or Core Needle Biopsies of Solid Tumors	17MA012
<b>CD3-CD28:</b> Bispecific Antibody for the Generation of CAR-T cells for Cancer Immunotherapy	17MA007
<b>IL-13R<math>\alpha</math>2:</b> CAR-T Cell Constructs (Chimeric Antigen Receptors) that Recognize IL-13R $\alpha$ 2	16MB069
<b>aAPC:</b> Artificial Antigen-Presenting Cells for Expanding TILs/MILs in Cancer Immunotherapy	16MB050
<b>aAPC:</b> Artificial Antigen-Presenting Cells Expressing CD3, CD28 and a Heparin-Binding Domain for Producing CAR-Ts	16MB049
<b>TLS:</b> Method of Using Chitosan Hydrogels with Chemokine-Releasing Microparticles or Stromal Cells to Bioengineer Tertiary Lymphoid Structures to Enhance the Immune System for Cancer Therapy	16MA028N
<b>TLR9:</b> CAR-T Cell Constructs (Chimeric Antigen Receptors) that Recognize TLR9	16MA025
<b>TIM3 Ligand Trap:</b> TIM-3-IgG4 Fusion Protein for the Treatment of Anemia in Low- or Intermediate (Int)-risk MDS Patients	16MA001
<b>Bromodomain:</b> Ex vivo Activation and Expansion of Antigen Specific T cells in the Presence of a Bromodomain Inhibitor	14MB100N
<b>Cancer Vaccine:</b> Full-Length Variant Survivin Vaccine Potentiates Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma	14MB098
<b>HDAC6:</b> Method of Using Histone Deacetylase 6 Inhibition for Enhancing T cell Function During Anti-Tumor Response and Tumor-Peptide Vaccination	14MA037N
<b>HDAC:</b> Combination Therapy of Melanoma with an HDAC Inhibitor and a Checkpoint Inhibitor	14MA027N
<b>S100A9:</b> CD33/IgG1 Chimera Antibody Trap to Neutralize S100A9 to Treat MDS	13MB041
<b>Vaccine:</b> Vaccines Using Synthetic Peptide-Poly IC Complexes that Elicit T-cell Responses Comparable to Live Vaccination	11MA013

Haskell Adler PhD MBA CLP  
Sr. Licensing Manager  
[haskell.adler@moffitt.org](mailto:haskell.adler@moffitt.org)  
(813) 745-6596

Charlie Shaw PhD  
Associate Director, Licensing  
[charlie.shaw@moffitt.org](mailto:charlie.shaw@moffitt.org)  
(813) 745-6639

Praba Soundararajan PhD  
Intellectual Property Manager  
[praba.soundararajan@moffitt.org](mailto:praba.soundararajan@moffitt.org)  
(813) 745-6776

**Antibodies:** MARCO Antibodies for Enhanced Dendritic Cell Vaccine Efficacy 07MB004

## PHARMACEUTICALS & BIOLOGICS

<b>β-Catenin/BCL9:</b> 1-Benzoyl 4-Phenoxypiperidines Small-Molecule Inhibitors of the β-Catenin/BCL9 Protein-Protein Interaction	21MA023
<b>p53:</b> Combination Therapy of Hypothermia and Chemotherapy to Treat Temperature Sensitive p53 Mutant Tumors	21MA021N
<b>BRD4 JAK2:</b> Sultam (cyclic sulfonamide) BRD4 JAK2 Inhibitors to treat myelofibrosis	21MA020N
<b>JAK2:</b> Novel JAK2 Inhibitor Piperadine Aniline Derivatives of Ruxolitinib to treat myelofibrosis	21MA004N
<b>TROLLS:</b> Inhibition Of TAp63 Regulated Oncogenic Long Noncoding RNAs (TROLLs) for the Treatment Of Cancer	20MB056N
<b>β-Catenin/BCL-9:</b> Acyl sulfonamide-containing Small Molecules that Inhibit the β-catenin/BCL9 Protein-Protein Interaction	20MB051N
<b>HPV E1:</b> Novel Use for Aminocoumarins as HPV Helicase E1 Inhibitors to Treat Cancer	20MB046
<b>CMG Helicase:</b> Novel Replicative CMG Helicase Inhibitors (CMGi) to Treat Solid Tumors	20MB046T2
<b>TAF1:</b> Novel TAF1 Inhibitors for the Treatment of Cancer	20MB037N
<b>ACK1:</b> Small molecule ACK1 inhibitors for the Treatment of Castrate Resistant Prostate Cancer	20MA015N
<b>CDK12/CDK13:</b> Novel Small Molecule Dual Inhibitors for CDK12/CDK13 for the Treatment of Triple Negative Breast Cancer	19MB064N
<b>β-catenin/BCL9:</b> Novel Small Molecules that Inhibit the β-catenin/BCL9 Interaction in breast cancer	19MB055
<b>β-Catenin/TCF:</b> Small Molecule Peptidomimetic Inhibitors of the Interaction of β-Catenin and T-Cell Factor	18MB076
<b>BRD4 JAK2:</b> Novel Second Generation BRD4/JAK2 Dual Inhibitors as Cancer Therapeutics	18MB053
<b>β-Catenin/TCF:</b> Small Molecule Inhibitors of the Interaction of β-Catenin and T-cell Factor	18MA018N
<b>Ubiquitin Bispecific Antibody:</b> Antibodies that Bring the E3 Ubiquitin Ligase into Close Proximity to Receptors to Induce the Receptor's Degradation	17MB056N
<b>XBP-1:</b> Method of XBP-1 Inhibition for the Treatment of Acute GVHD and Solid Organ Rejection	17MB051
<b>β-Catenin/BCL-9:</b> Small Molecule Inhibitors of the Interaction of β-Catenin and BCL-9	17MA014

Haskell Adler PhD MBA CLP  
Sr. Licensing Manager  
[haskell.adler@moffitt.org](mailto:haskell.adler@moffitt.org)  
(813) 745-6596

Charlie Shaw PhD  
Associate Director, Licensing  
[charlie.shaw@moffitt.org](mailto:charlie.shaw@moffitt.org)  
(813) 745-6639

Praba Soundararajan PhD  
Intellectual Property Manager  
[praba.soundararajan@moffitt.org](mailto:praba.soundararajan@moffitt.org)  
(813) 745-6776

## PHARMACEUTICALS & BIOLOGICS

<b>HDAC, BTK:</b> Method of Using HDAC Inhibitors, Alone or in Combination with BTK Inhibitors, for Treating Chronic Lymphocytic Leukemia (CLL)	16MA023N
<b>Aurora/JAK2:</b> Dual JAK2 and Aurora A Kinase Inhibitor for GVHD Prophylaxis	16MA005N
<b>Ras/Raf:</b> Stapled Peptides Designed to Inhibit the K-Ras/Raf Interaction	15MA012
<b>Ras:</b> Inhibitors of the Binding of GTP to Oncogenic Mutant K-Ras	15MA011
<b>WEE1:</b> Small Molecule WEE1 Inhibitor to Treat Cancer that Inhibits WEE1 Phosphorylation of H2B but not Cdc2	14MB092
<b>YAP1/OCT4:</b> Small Molecule Inhibitors of the Protein-protein Interaction of YAP1 and OCT4 to Treat Cancer	14MB075N
<b>HDAC, BTK:</b> Method of Using HDAC Inhibitors, Alone or in Combination with BTK Inhibitors, for Treating Non-Hodgkin's Lymphoma (NHL)	14MB086N
<b>BRD4 JAK2:</b> Novel BRD4/JAK2 Dual Inhibitors as Cancer Therapeutics	14MB069
<b>Anti-Infectives:</b> Symmetrical Synthetic Marinopyrroles as Anti-MRSA Therapeutics	12MB110
<b>STAT3:</b> STAT3 Dimerization Inhibitors	12MB098
<b>IRE-1:</b> Novel Small Molecule Inhibitors of IRE-1 for Treatment of B-Cell Cancer	12MB089
<b>Mcl-1/Bcl-xL:</b> Cyclic, Symmetrical and Asymmetrical Marinopyrroles as Anti-Cancer Agents	12MA035N
<b>HDAC6:</b> Small Molecule Histone Deacetylase 6 Inhibitor with a Substituted Aryl Urea Cap Group	12MA030
<b>Proteasome:</b> Non-Covalent and Reversible Proteasome Inhibitors with an Oxadiazole-Isopropylamide Core	10MB083
<b>FT/GGT:</b> Farnesyltransferase/ Geranylgeranyltransferase Dual Inhibitor	10MB048
<b>LPAAT:</b> Lysophosphatidic Acid Acyltransferase-Beta Inhibitors to Treat Pancreatic Cancer	10MA019N
<b>Mcl-1:</b> Asymmetrical Marinopyrroles as Anti-Cancer Agents	10MA018N
<b>pH:</b> Method of Inhibiting Metastasis with Systemic Non-Volatile Buffers to Reduce Intratumoral pH	09MB048
<b>Aurora:</b> Aurora A Kinase Inhibitors	09MA037
<b>Rho Kinase:</b> Pyridylthiazole-Based Ureas As Inhibitors of Rho Associated Protein Kinase (ROCK)	09MA015

Haskell Adler PhD MBA CLP  
Sr. Licensing Manager  
[haskell.adler@moffitt.org](mailto:haskell.adler@moffitt.org)  
(813) 745-6596

Charlie Shaw PhD  
Associate Director, Licensing  
[charlie.shaw@moffitt.org](mailto:charlie.shaw@moffitt.org)  
(813) 745-6639

Praba Soundararajan PhD  
Intellectual Property Manager  
[praba.soundararajan@moffitt.org](mailto:praba.soundararajan@moffitt.org)  
(813) 745-6776

## CLINICAL DECISION SUPPORT TOOLS

<b>Topoisomerase II:</b> Method of Enhancing Topoisomerase II Inhibition by Inhibiting the Nuclear Export of Topoisomerase II Alpha	08MB014 10MB078
<b>Machine Learning:</b> A Rapid and Non-invasive Diagnostic to Predict PD-L1 Status Using Deep Learning Radiomics	19MB053
<b>Math Model:</b> A Radiomics Based Diagnostic to Predict Treatment Outcomes in Lung Cancer	19MB040N
<b>Math Model:</b> A Diagnostic that Predicts Treatment Outcome and Personalize CAR-T Therapies	19MA038N
<b>Math Model:</b> A Diagnostic that Predicts Efficacy and Progression Free Survival in CAR-T Treated Patients	19MA037N
<b>Math Model:</b> A Diagnostic for Lesion Heterogeneity Classification for Informed Treatment Decision	19MA034N
<b>Software:</b> Deep Neural Network to Locate and Label Brain Tumors Enables Surgeons to Remove Tumors More Effectively	19MA019
<b>Math Model:</b> Predict Patient-Specific Radiotherapy Responses Using a Proliferation Saturation Index in an Adaptive Bayesian Approach	18MB083N
<b>Math Model:</b> Methods for the Treatment of Prostate Cancer Using Intermittent Adaptive Therapy	18MB055N
<b>Software:</b> A Pathologist Tool for Alignment of Serial Whole Slide Histology Images	18MA012N
<b>Software:</b> A Quantitative Framework to Identify Radiation Targets for Cancer Treatment that Synergize with Immunotherapy (Abscopal Effect)	14MA022
<b>Software:</b> Decision Support Tool for Oncology Treatment Using Mathematical Simulations	13MB073
<b>Software:</b> Improved Detection of Lung Function and Management of Lung Cancer Radio Therapy	10MA037N

## DIAGNOSTICS

<b>Diagnostic:</b> Kits and Methods for Performing an ELISPOT to Detect Coronavirus	21MA019N
<b>Protein Diagnostic:</b> Diagnostic to detect Leptomeningeal Disease	20MB040N
<b>Molecular Imaging Agent:</b> A Novel Fluorescence Molecular Imaging Agent for Intraoperative Margin Assessment in Breast Cancer	20MA008N
<b>Cell Imaging:</b> Diagnostic for Predicting Response to Therapies in Multiple Myeloma	19MB057 13MB048

Haskell Adler PhD MBA CLP  
 Sr. Licensing Manager  
[haskell.adler@moffitt.org](mailto:haskell.adler@moffitt.org)  
 (813) 745-6596

Charlie Shaw PhD  
 Associate Director, Licensing  
[charlie.shaw@moffitt.org](mailto:charlie.shaw@moffitt.org)  
 (813) 745-6639

Praba Soundararajan PhD  
 Intellectual Property Manager  
[praba.soundararajan@moffitt.org](mailto:praba.soundararajan@moffitt.org)  
 (813) 745-6776

## DIAGNOSTICS

<b>Methylation Status Diagnostic:</b> Diagnostic to Predict Response to Immunotherapy	19MB052
<b>Companion Diagnostic:</b> Companion Diagnostic to Predict Response to Immunotherapy Based on the Methylation Status	19MB052T2
<b>Genetic Signature:</b> Distinguishing Urothelial Carcinoma from Squamous Cell Carcinoma (Primary Lung Carcinoma and Metastatic Head & Neck Carcinoma)	17MB044
<b>Genetic Biomarker:</b> PTEN Loss of Expression as a Biomarker Response to GGTI-2418 Treatment	17MA025
<b>Molecular Imaging:</b> Predicting Response to Adjuvant Ipilimumab Treatment in Melanoma Using a Novel Algorithm to Analyze Nitric Oxide Levels in Peripheral Blood Immune Cells	17MA002N
<b>miRNA Diagnostic:</b> miRNA Signature for Non-invasive Early Detection of Malignancy in IPMN	17MA001
<b>miRNA Diagnostic:</b> Signature to Predict Progression of Barrett's Esophagus to Esophageal Dysplasia or Adenocarcinoma	16MB066
<b>Molecular Imaging Probe:</b> Novel IDO1-Targeting Cancer Diagnostic PET Imaging Agent	16MB044
<b>Protein Biomarker:</b> Predicting Restoration of Sensitivity to Erythropoietin in MDS Patients by Lenalidomide	16MB042
<b>Protein Biomarker:</b> Measuring MRE11 in Muscle-Invasive Bladder Cancer to Predict whether Cystectomy (Bladder Removal) would have a Better Outcome than Bladder-Sparing Therapy with Chemoradiation	16MB041
<b>Genetic Signature:</b> Distinguishing Primary Lung Carcinoma from Metastatic Head & Neck Carcinoma	16MB040
<b>Protein Biomarker:</b> Diagnostic for Progression of MDS to AML Using PD-1 or PD-L1 Expression	15MB065
<b>Molecular Imaging Probe:</b> In vivo Positron Emission Tomography-Based Perfusion/Blood Pool Imaging Using Labeled Erythrocytes	15MB042N
<b>Diagnostic:</b> S100A9 Serum Concentration Levels Predict Lenalidomide Response Duration	15MA031N
<b>Diagnostic:</b> Intracellular S100A9 Alone or NLRP3 Inflammasome Activation as MDS Biomarkers	15MA021N
<b>Molecular Imaging:</b> Monoacylated TLR2 Ligand Fluorescent Probe for Detection and Tumor Removal in Pancreatic Cancer Patients	15MA015
<b>Genetic Signature:</b> Microarray-Based Gene Expression Profiling to Predict Tumor Sensitivity to Radiotherapy	14MA052N
<b>Protein Biomarker:</b> Expression of WEE1 and PAXIP1 to Predict Respond to WEE1 Inhibitors	14MA001
<b>miRNA Diagnostic:</b> Blood Based microRNA Assay to Detect Malignant Intraductal Papillary Mucinous Neoplasms (IPMNs)	13MB078

Haskell Adler PhD MBA CLP  
 Sr. Licensing Manager  
[haskell.adler@moffitt.org](mailto:haskell.adler@moffitt.org)  
 (813) 745-6596

Charlie Shaw PhD  
 Associate Director, Licensing  
[charlie.shaw@moffitt.org](mailto:charlie.shaw@moffitt.org)  
 (813) 745-6639

Praba Soundararajan PhD  
 Intellectual Property Manager  
[praba.soundararajan@moffitt.org](mailto:praba.soundararajan@moffitt.org)  
 (813) 745-6776



## DIAGNOSTICS

<b>Molecular Imaging:</b> PET Probes of Radiofluorinated Carboximidamides for IDO-Targeted Imaging	13MB056N
<b>Molecular Imaging:</b> Novel Imaging Software Diagnostic to Determine Survival in Glioblastoma	13MB055
<b>Molecular Imaging:</b> Texture Features Low-Dose CT Images for Pulmonary Nodule Diagnosis	13MB054
<b>Imaging:</b> Decision Support Tool for Oncology Treatment that Analyzes Radiological Images	13MB047
<b>Genetic Signature:</b> Predicting Recurrence and Benefit From Adjuvant Chemo in Colorectal Cancer	13MA036
<b>Multiplex Diagnostic:</b> RNA Sequencing and Mass Spectrometric Method for Detecting Minimal Residual Disease in Multiple Myeloma	13MA009
<b>Protein Diagnostic:</b> Phosphorylated STAT3 Protein as a Biomarker of GVHD	13MA002
<b>Molecular Imaging Probe:</b> A Novel <sup>18</sup> F Scaffold for Preparing Targeted PET Imaging Probes	12MB104
<b>Genetic Signature:</b> E2F/Rb Pathway Signature to Predict Benefit from Adjuvant Chemo in NSCLC	12MA069
<b>Protein Diagnostic:</b> Quantum Dots Conjugated with Antibodies for Early Cancer Detection	12MA011N
<b>Protein Diagnostic:</b> Mass Spectrometry Diagnostic for BRAF and Heat Shock Proteins	11MB087N
<b>Genetic Signature:</b> Predicting Response to Cancer Immunotherapy	11MB069
<b>Molecular Imaging Probe:</b> Intraoperative Detection of Pancreatic Cancer Using Targeted Fluorescent Probes	11MB064
<b>Molecular Imaging Probe:</b> Surrogate Markers for Colon Adenoma and Adenocarcinoma	11MA026N
<b>Imaging:</b> Digital Pathology Tool to Grade Breast Cancer Histological Images	11MA022
<b>Protein Diagnostic:</b> Protein-Protein Interaction (PPI) Biomarkers	11MA014
<b>Molecular Imaging Probe:</b> Fluorescent and MRI Targeted Probes for the Melanocortin Receptor 1 on Melanomas, and Micelle Complexes for Drug Delivery	10MB069N
<b>Molecular Imaging Probe:</b> Non-Invasive Detection of Breast Cancer in Lymph Nodes	10MA024
<b>Genetic Signature:</b> Lymph Node Formation for Prognosis of Colorectal Cancer	09MA014
<b>Antibody Diagnostic:</b> Monitoring Multiple Myeloma Progression and Recurrence	08MA005

Haskell Adler PhD MBA CLP  
 Sr. Licensing Manager  
[haskell.adler@moffitt.org](mailto:haskell.adler@moffitt.org)  
 (813) 745-6596

Charlie Shaw PhD  
 Associate Director, Licensing  
[charlie.shaw@moffitt.org](mailto:charlie.shaw@moffitt.org)  
 (813) 745-6639

Praba Soundararajan PhD  
 Intellectual Property Manager  
[praba.soundararajan@moffitt.org](mailto:praba.soundararajan@moffitt.org)  
 (813) 745-6776

## DEVICES, TOOLS & SOFTWARE

<b>Software:</b> Cancer BERT Network (caBERTnet): A Question-and-Answer System to Extract Data from Free-Text Pathology Reports	21MA031
<b>Life Science Tool:</b> Diazirine reagents as Single and Double Nitrogen Transfer Reagents for Decarboxylative Amination	19MA030N
<b>Med Device:</b> Snowflake Shaped Drug Infusion Device for Brain Cancer	19MA010
<b>Med Device:</b> Biopsy Needle with Internal Ridges that Lead to a Higher Tissue Specimen Retrieval Rate	18MB047
<b>Copyright:</b> Energize mBC: Web-Based Program to Treat Fatigue in Metastatic Breast Cancer Patients	17MC003
<b>Med Device:</b> Novel Endotracheal Tube Intubating Stylet	16MA021
<b>Med Device:</b> Improved Pigtail Drainage Catheter for Percutaneous Fluid Aspiration	15MA034
<b>Software:</b> Negative Information Storage Model for Genomic Data	15MA033
<b>Med Device:</b> Expandable Intervertebral Cage for Spinal Fusion	14MB067N
<b>Software:</b> Real-Time Visualization Software Enables Surgeons to “See-Through” the Patient and Remove Tumors More Effectively	14MA004N
<b>Software:</b> BMT Research Analysis Information Network (BRAIN) Automates Submission of AGNIS/CIBMTR Forms	13MB053
<b>Software:</b> Automated Technique for Generating BIRADS Scores from Mammograms	13MA025
<b>Med Device:</b> Improved Enteral Feeding Tube and Retention Disc to Reduce Dislodgement & Infection	13MA001
<b>Software:</b> Method for Improving the Accuracy of Charged Particle Beam Radiotherapy	12MB072
<b>Med Device:</b> Improved Endotracheal Tube to Diagnose Airway Edema (Swelling)	11MA052
<b>Med Device:</b> Bidirectional Expandable Intervertebral Cages for Spinal Fusion	11MA021T2
<b>Med Device:</b> Minimally Invasive Spinal Fusion Using a Transdiscal Screw System	11MA021
<b>Med Device:</b> Pump-Assisted High Flow Rate Isolated Limb Infusion for Regional Cancer Treatment	11MA017N
<b>Med Device:</b> Muscle Stapler	10MB065N
<b>Med Device:</b> Handheld Radioisotope Identification Device (RIID)	10MB054
<b>Research Tool:</b> Novel Electroporation Buffer Formulation for Enhanced Efficiency and Viability	05B141

Haskell Adler PhD MBA CLP  
Sr. Licensing Manager  
[haskell.adler@moffitt.org](mailto:haskell.adler@moffitt.org)  
(813) 745-6596

Charlie Shaw PhD  
Associate Director, Licensing  
[charlie.shaw@moffitt.org](mailto:charlie.shaw@moffitt.org)  
(813) 745-6639

Praba Soundararajan PhD  
Intellectual Property Manager  
[praba.soundararajan@moffitt.org](mailto:praba.soundararajan@moffitt.org)  
(813) 745-6776